HONG KONG – A Chinese biotech company has plans to further explore the potential of immuno-oncology products through a licensing deal with a U.S. pharma company dedicated to oncology. Read More
SAN FRANCISCO – Displaying two radiographs side by side on a screen, Kite Pharma Inc.'s chief medical officer, David Chang, illustrated the profound potential of T-cell therapies in treating advanced cancers. Read More
NEW DELHI – A recent acquisition by a leading Indian biotech company could spur drug development and clinical trials for treatments for brain and central nervous system diseases. The incidence of both ailments is on the rise. Read More
LONDON – New knowledge of the way in which bacteria that cause meningitis stick to human cells and then enter them could also lead to novel therapies to prevent cancer metastasis and slow the progression of Alzheimer's disease. Read More
LONDON – One of the academic lynchpins of UK biotech, John Martin, has attracted £15.5 million (US$24.9 million) in private equity for Magnus Life Sciences Ltd., a start-up shaped to overcome his frustrations at current shortcomings and gaps in the process of translating research from lab to bedside. Read More
SAN FRANCISCO – Attendees of the 13th BIO Investor Forum held at the Palace Hotel here crowded into the Twin Peaks meeting room to eat their boxed lunches on Tuesday as they listened to one company's accelerated response to the Ebola virus outbreak. Read More
NEW DELHI – India's drug pricing regulator has withdrawn a series of guidelines that capped prices of diabetes, cardiovascular disease and asthma drugs. The sudden U-turn in policy was timed ahead of a recent visit by Indian Prime Minister Narendra Modi to the U.S. and has sharply divided the pharmaceutical industry that welcomes the move and public health analysts that oppose it. Read More
SHANGHAI – Sanofi SA, of Paris, has chosen a Shanghai address for its Asia Pacific R&D Hub. Its fifth hub, it will coordinate a complex research network across 12 Asian countries, and 50 collaborations pursuing the pharma's model of borderless, "open innovation." Read More
Northwest Biotherapeutics Inc., of Bethesda, Md., inked an agreement to sell an undisclosed existing institutional shareholder approximately $11.5 million of newly issued common shares at $5.05 apiece. Read More
Hyperion Therapeutics Inc., of Brisbane, Calif., and Clal Biotechnology Industries Ltd. (CBI), of Ramat Gan, Israel, said they entered an interim agreement in order to attempt to resolve the disputes between them and to allow CBI to evaluate whether there is any clinical efficacy to, and a potential regulatory path forward for, Diapep277 that a party other than Hyperion may wish to pursue. Read More
EMD Serono, the biopharmaceutical division of Merck KGaA, of Darmstadt, Germany, the Institute of Cancer Research (ICR) and the Wellcome Trust, London, jointly announced a co-development and license agreement that builds on two independent research programs at both the ICR and EMD Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family. Read More
Bio-Path Holdings Inc., of Houston, said it completed cohort six of its phase I trial testing Liposomal Grb-2 in blood cancers, showing the compound to be safe and well tolerated, with signs of anti-leukemia activity, and it now plans to move into phase II testing by the end of this year. Read More
